Addex's Chronic Cough Drug Candidate Shows Robust Efficacy in Non-Human Primate Study
summarizeSummary
Addex Therapeutics announced robust anti-tussive activity for its novel GABAB PAM drug candidate in a non-human primate chronic cough model. The candidate significantly reduced citric acid-induced cough frequency, demonstrating efficacy similar to baclofen and appearing superior to other treatments like nalbuphine, codeine, or a P2X3 inhibitor in previously reported guinea pig models, with better tolerability. This positive preclinical data for Addex's independent GABAB PAM program for chronic cough is a material de-risking event for the program, especially for a clinical-stage biopharmaceutical company with a small market capitalization. It provides strong evidence for the therapeutic potential of the candidate and supports its advancement towards human clinical trials. Investors will now look for updates on IND filing and the initiation of human clinical trials for this chronic cough program.
At the time of this announcement, ADXN was trading at $7.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $5.41 to $12.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.